Dr. Millan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
CIRM- Lake Merrit Plaza
1999 Harrison St.
Oakland, CA 94612Phone+1 415-205-7968
Summary
- Changing the face of medicine – the CIRM 2018 Annual Report
https://www.cirm.ca.gov/about-cirm/2018-annual-report
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Abdominal Transplant Surgery, 1998 - 2000
- Beth Israel Deaconess Medical CenterResidency, Surgery, 1990 - 1997
- Harvard Medical SchoolPost-Doctoral Fellowship, 1994 - 1996
- Rutgers New Jersey Medical SchoolClass of 1990
- Duke UniversityBS, Zoology, Cum laude, 1982 - 1986
Certifications & Licensure
- CA State Medical License Active through 2013
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM) Start of enrollment: 2005 Jun 01
Publications & Presentations
PubMed
- 54 citationsThe duodenal microbiome is altered in small intestinal bacterial overgrowth.Gabriela Leite, Walter Morales, Stacy Weitsman, Shreya Celly, Gonzalo Parodi
Plos One. 2020-07-09 - 161 citationsMixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation.Maria T. Millan, Judith A. Shizuru, Petra Hoffmann, Sussan Dejbakhsh-Jones, John D. Scandling
Transplantation. 2002-05-15
Other
- Annual ReportCIRM
https://www.cirm.ca.gov/sites/default/files/files/about_cirm/CIRM%202017%20Annual%20Report_Web.pdf
1/15/2018
Authored Content
- SF Chronicle- Interview about Stem Cells8/30/2018
Press Mentions
- How CIRM-Funded Research Is Bringing a Lifesaving Gene Therapy to a 5-Year-OldMay 3rd, 2023
- Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCEDApril 28th, 2023
- Making Transplants Easier for Kids, and Charting a New Approach to Fighting Solid TumorsNovember 30th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: